NEW YORK (GenomeWeb News) – A personalized molecular medicine company offering physicians access to clinically actionable genetic tests has been launched.
The company called Genection was launched today by its owner, molecular diagnostics firm Invivoscribe Technologies. Genection offers both routine and esoteric genetic tests, exome and whole-genome sequencing, cancer somatic mutation testing, and pharmacogenomics.
Because the Genection model is not payor-driven, it said, it can provide doctors access to genetic tests that are currently unavailable, overlooked, or inaccessible through their patients' health plans and healthcare institutions.
The privately held company added that it has agreements in place with several CLIA- and CAP-certified laboratories, including ARUP Laboratories, Foundation Medicine, Cypher Genomics, Invivoscribe's wholly owned subsidiary the Laboratory for Personalized Molecular Medicine and LPMM's laboratory in Martinsried, Germany. It also has relationships with Illumina and Ambry Genetics and agreements with "a consortium" of genetic counselors.
"In order to make personalized molecular medicine a clinical reality, new platforms need to be developed for the delivery of healthcare. Genection's mission seeks to accelerate this adoption process," Genection Chief Medical Officer Bradley Patay said in a statement. "The combination of CLIA-validated genetic testing, whole-exome or whole-genome sequencing, and broad targeted assays, along with critical bioinformatics, analytic tools, and interpretative guidelines will contribute to timely definitive diagnoses for patients with rare, unexplained diseases or complex diseases; in essence, this integration will speed delivery of genomic test results and improve patient care."
The San Diego-based company will serve as the gateway to the Together We Cure, a global initiative aimed at developing treatments for acute myeloid leukemia by facilitating the sharing of clinical information by AML patients and clinicians.